利格列汀片联合黄葵胶囊治疗对早期糖尿病肾病患者CysC、Hcy的影响  

Effect of linagliptin tablets combined with Huangkui capsules on CysC and Hcy of patients with early diabetic nephropathy

作　　者：王欣 WANG Xin(Department of Nephrology,Panjin Central Hospital,Panjin 124000,China)

机构地区：[1]盘锦市中心医院肾内科,124000

出　　处：《中国现代药物应用》2024年第16期107-109,共3页Chinese Journal of Modern Drug Application

摘　　要：目的观察早期糖尿病肾病患者采取利格列汀片联合黄葵胶囊进行治疗对其胱抑素C(CysC)以及同型半胱氨酸(Hcy)的影响。方法回顾性收集70例早期糖尿病肾病患者临床资料作为研究对象,根据治疗方案的不同将其分为对照组和研究组,每组35例。对照组应用利格列汀片治疗,研究组接受利格列汀片联合黄葵胶囊治疗。对比两组治疗前后CysC以及Hcy水平改变情况。结果研究组治疗后的CysC(1.14±0.23)mg/L、Hcy(9.25±1.75)μmol/L显著低于对照组的(1.82±0.63)mg/L、(12.84±2.26)μmol/L,对比存在统计学差异(P<0.05)。结论为早期糖尿病肾病患者提供利格列汀片联合黄葵胶囊治疗,能够有效降低CysC以及Hcy水平,提升疾病治疗效果。Objective To observe the effect of linagliptin tablets combined with Huangkui capsules on cystatin C(CysC)and homocysteine(Hcy)of patients with early diabetic nephropathy.Methods The clinical data of 70 patients with early diabetic nephropathy were retrospectively collected and divided into a control group and a study group according to different treatment regimens,with 35 cases in each group.The control group was treated with linagliptin tablets,and the study group was treated with linagliptin tablets combined with Huangkui capsules.The changes of CysC and Hcy levels before and after treatment were compared between the two groups.Results After treatment,the study group had CysC of(1.14±0.23)mg/L and Hcy of(9.25±1.75)μmol/L,which were significantly lower than(1.82±0.63)mg/L and(12.84±2.26)μmol/L in the control group,and the difference was statistically significant(P<0.05).Conclusion Linagliptin tablets combined with Huangkui capsules for early diabetic nephropathy patients can effectively reduce the levels of CysC and Hcy and improve the therapeutic effect.

关 键 词：早期糖尿病肾病 利格列汀片 黄葵胶囊 胱抑素C 同型半胱氨酸 治疗效果 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]